Post-Congress webinars
Post IMS 2023 round table debate by the IACH
Meral Beksac, Luciano J. Costa, Thierry Facon, Irene Ghobrial, Suzanne Lentzsch, María-Victoria Mateos, Hira Mian, Mohamad Mohty
October 19, 2023
Post ASCO/EHA 2023 Roundtable Discussion on Multiple Myeloma: Focus on Immunotherapy (French)
Eileen Boyle, Thierry Facon, Jean luc Harousseau, Salomon Manier, Murielle Roussel, Mohamad Mohty
June 28, 2023
Post ASCO/EHA 2023 Roundtable Discussion on the latest updates in MDS
Uma Borate, Andrew M. Brunner, Amer Zeidan
June 27, 2023
Post ASCO/EHA 2023 Roundtable Discussion: Targeting Bruton Tyrosine Kinase in CLL in 2023 and Beyond – Problems and Promises
Arnon Kater, Mohamed Kharfan Dabaja, Carsten Utoft Niemann, Mohamad Mohty
June 13, 2023
Post ASCO/EHA 2023 Roundtable Discussion: Immunotherapy for Myeloma
Nizar Bahlis, Hermann Einsele, Thierry Facon, Hira Mian, Joshua Richter, Paula Rodríguez Otero, Kwee Yong, Mohamad Mohty
June 12, 2023
Best of ASH22 AML
Naval Daver
Feb. 16, 2023
POST ASH22 MDS summary
Amer Zeidan
Feb. 9, 2023
POST ASH22 MPN summary
Naveen Pemmaraju
Feb. 2, 2023
POST ASH22 cellular therapy
Bipin Savani
Feb. 1, 2023
POST ASH22 transplant summary
Arnon Nagler
Jan. 17, 2023
Multiple Myeloma: a post-ASH22 summary
Mohamad Mohty
Jan. 5, 2023
The IACH post #ASH22 take-home messages in Leukemia, Lymphoma and Myeloma
Ali Bazarbachi, Didier Blaise, Jean-Luc Harousseau, Mohamed Kharfan Dabaja, Salomon Manier, María Victoria Mateos, Amer Zeidan
Dec. 13, 2022
The IACH Post IMS/IMW 2022 round table debate
Luciano Costa, Thierry Facon, Jean luc Harousseau, Salomon Manier, Maria Victoria Mateos Manteca, Aurore Perrot, Noopur Raje, Cyrille Touzeau, Mohamad Mohty
Sep. 13, 2022
The IACH Post ASCO/EHA 2022 Roundtable Discussion: a Focus on Multiple Myeloma
Nizar Bahlis, Meral Beksac, Herman Einsele, Thierry Facon, Salomon Manier, María Victoria Mateos, Philippe Moreau, Rakesh Popat, Cyrille Touzeau, Saad Usmani
June 21, 2022
Chronic lymphocytic leukemia at ASH21: What’s new?
Romain Guieze
Feb. 10, 2022
Post #ASH21 by the IACH: a focus on MDS
Amer Zeidan
Jan. 27, 2022
Post #ASH21 by the IACH: CAR-T cells
Prof. Bipin Savani
January 19, 2022
Post #ASH21 by the IACH: Hematopoietic Cell Transplantation
Prof. Bipin Savani
January 18, 2022
Myeloma news live from #ASH21 by the IACH – Part 2
Dr. Salomon Manier and Prof. Mohamad Mohty
December 13, 2021
Myeloma news live from #ASH21 by the IACH – Part 1
Dr. Salomon Manier, Prof. Irene Ghobrial and Prof. Mohamad Mohty
December 12, 2021
The IACH post-IMW 2021 Roundtable Discussion
Nizar Bahlis, Luciano Costa, Jean Luc Harousseau, Shaji Kumar, Salomon Manier, María Victoria Mateos, Mohamad Mohty, Cyrille Touzeau, Saad Usmani
October 12, 2021
Prof. Mohamad Mohty
July 27, 2021
Prof. Arnon Nagler
Prof. Bipin Savani
Prof. Mohamad Mohty
Latest advances in HCT and cellular therapy: a post-TCT summary part II- GVHD, CART and Gene Therapy
Prof. Bipin Savani
Latest advances in stem cell transplantation and cellular therapy: a post-TCT summary
Prof. Bipin Savani
Allogeneic Stem Cell Transplantation: an update from ASH 2019
Prof. Arnon Nagler, M.D., M.Sc.
Myeloma update: A flavor of ASH 2019
Mohamad Mohty, MD, PhD
Anti-CD38 monoclonal antibodies in multiple myeloma: a post ASCO/EHA 2019 summary
Mohamad Mohty, MD, PhD
The Myeloma Summary Post ASH 2018
Mohamad Mohty, MD, PhD